Active ingredient
Semaglutide
Semaglutide produces ~15% mean weight loss at 68 weeks (STEP-1) β the 2nd-most-effective GLP-1 agent in 2026, behind tirzepatide (~22%) and ahead of liraglutide (~8%).
Brand names + indications
Semaglutide is sold under 3 brand names, each with its own indication + maximum dose.
How it works
Semaglutide is a long-acting GLP-1 receptor agonist that mimics the gut hormone GLP-1 at supra-physiologic levels. It slows gastric emptying, increases insulin secretion, decreases glucagon, and signals satiety to the brain via hypothalamic GLP-1 receptors.
Pivotal trial efficacy
β14.9%
Mean weight loss
The pivotal phase-3 trial for Semaglutide is STEP-1, which showed mean body-weight reduction at the maintenance dose.
More on Semaglutide
People also ask
Common questions readers ask
- Does Ozempic cause hair loss?
- Not directly. Hair shedding (telogen effluvium) is reported by some patients ~3 months into rapid weight loss β typical of any rapid-weight-loss state, not unique to GLP-1. Full evidence-graded answer
- Can you drink alcohol on Wegovy?
- No hard contraindication, but alcohol tolerance often drops sharply on GLP-1. Many patients also report reduced desire for alcohol β likely a secondary effect of GLP-1 on the brain reward system. Full evidence-graded answer
- Can I take GLP-1 while pregnant?
- No. All FDA-approved GLP-1s carry a pregnancy contraindication. Stop GLP-1 at least 2 months before planned conception due to its long half-life. Full evidence-graded answer
- Is it safe to take GLP-1 long-term?
- Liraglutide has 15+ years of post-marketing data (Victoza approved 2010). Semaglutide has 8+ years (Ozempic approved 2017). No new class-wide safety signals have emerged in extended follow-up. Chronic use is the FDA-approved indication for both T2D and obesity. Full evidence-graded answer
- Do I need to exercise on Wegovy?
- Yes β resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable. Full evidence-graded answer